Side-effect playbook: what's normal, what's not, what to do

The three-bucket framework

Every peptide side effect falls into one of three buckets, and what you do next depends entirely on the bucket.

• Expected and dose-related — common at the labeled dose, resolves with titration or time. Adjust, do not stop.
• Idiosyncratic but not dangerous — happens to a minority, often non-dose-related, usually tolerable. Decide whether the benefit is worth it.
• Stop-immediately — uncommon but serious. Discontinue, document, contact a clinician.

Injection site reactions

Mild redness, itching, or a small bump that resolves in 24 hours is normal subq response and almost always benign. Rotate sites (abdomen quadrants, upper thigh), wipe with alcohol, use a fresh needle every injection, and warm the vial to room temperature briefly before drawing.

Stop-immediately signals: spreading redness, warmth, hardness, fever, or pus — these are infection, not injection. Same for a hot, painful, sustained nodule that does not resolve in 72 hours.

GLP-1 GI protocol

Nausea, fullness, reflux, and constipation are the GLP-1 signature. They are dose-related and almost always resolve with titration. The protocol that works for most users:

• Stay on the labeled escalation schedule. Do not push to the next dose if the current one is still producing GI symptoms.
• Smaller, lower-fat meals. Eat slowly. Stop at 'enough', not 'full'.
• Hydration and electrolytes — dehydration amplifies nausea and is common because thirst falls with appetite.
• Fiber and a stool softener for constipation; ginger for nausea.
• Stop-immediately signals: sustained severe abdominal pain that radiates to the back (lipase, rule out pancreatitis), persistent vomiting that prevents hydration, jaundice (gallbladder).

GH secretagogue side effects

The ipamorelin / CJC-1295 / tesamorelin / MK-677 family share a set of dose-related effects driven by GH/IGF-1 elevation.

• Water retention and peripheral edema — early, common, usually resolves within 1–2 weeks of dose reduction.
• Tingling or numbness in fingers — early carpal tunnel signal. Drop the dose; if persistent, stop.
• Joint aches — IGF-1 driven; usually a sign you have pushed dose too high.
• Rising fasting glucose — chronic GH elevation impairs insulin sensitivity. Recheck labs at 6–8 weeks.
• Increased appetite (especially MK-677, GHRP-6) — feature for some users, bug for others.

Melanotan II side effects

MT-II is among the most side-effect-heavy peptides in the category, which is why titration and timing matter so much.

• Nausea and flushing on injection — dose-related, mitigated by injecting before bed and starting at very low doses (0.1–0.25 mg).
• Darkening of existing moles — expected; problematic because it complicates melanoma surveillance. Get a dermatology baseline before starting.
• Spontaneous erections (men) — common, dose-related.
• Decreased appetite — desired by some, unwelcome for others.
• Stop-immediately signals: any new or changing mole, persistent blood pressure elevation, severe nausea that does not subside with titration.

PT-141 / Bremelanotide

Nausea is the dose-limiting side effect — affects roughly 40% of users at labeled doses. Flushing and headache are common. Transient blood pressure elevation is the signal to watch.

Stop-immediately: priapism (erection >4 hours) is an emergency. Sustained blood pressure changes warrant discontinuation and clinical review.

Healing peptides (BPC-157, TB-500)

The class has the cleanest tolerability profile of anything covered on this site. Most reported side effects are mild and resolve within days:

• Fatigue or 'flu-like' feeling in the first week — usually subsides.
• Transient appetite changes.
• Mild dizziness on initial doses.
• Stop-immediately signals: any new or changing skin lesion (theoretical angiogenic concern), unexplained persistent symptoms inconsistent with normal patterns.

Nootropic peptides (Selank, Semax)

Nasal route can cause local irritation, particularly with frequent dosing. Some users report headache or rebound fatigue. Stop if you experience persistent mood changes, sleep disruption that does not normalize, or any neurologic symptom that is new.

When in doubt: the universal triage

Three questions, every time:

• Is the symptom expected for this peptide and this dose? If yes, titrate.
• Is it tolerable and resolving? If yes, observe.
• Is it new, severe, or progressing? If yes, stop the peptide and contact a clinician with the labels, dose, and symptom timeline in hand.